Full history for every metric is available with a Kvantra account
Ocean Biomedical, Inc. (OCEAW)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | - | 0 | 0 |
| Operating profit | $m | -4 | - | |||||
| Net profit | $m | -0 | -2 | -62 | 1 | - | -3 | - |
| EPS reported | $ | -0.12 | - | |||||
| Operating cashflow per share | $ | -0.15 | -0.15 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.15 | -0.15 | |||||
| Free cash flow | $m | -4 | -4 | |||||
| Net debt | $m | 16 | 9 | |||||
| Book value equity | $m | -98 | -92 | |||||
| Book value per share | $ | -3.55 | -3.36 | |||||
| Number of shares | m | 27.5 | 27.5 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.40 | -0.22 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -9.29 | -5.03 | |||||
| EV/EBITDA LTM | x | -7.39 | -1.00 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -21.70% | -402.77% | |||||
| FCF Yield | % | -10.77% | -19.86% | |||||
| Quality | ||||||||
| ROE | % | 3.38% | 3.50% | |||||
| ROIC | % | 22.76% | 0.00% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.26 | -0.43 | |||||
| Net Debt/EBITDA | x | -2.16 | 0.00 | |||||
| EBIT/Net interest | x | 1.86 | 0.00 | |||||
| Net debt/market cap | % | 41.41% | 42.03% | |||||
| Net debt/Equity | x | -0.16 | -0.09 | |||||
| Gross debt/equity | x | -0.17 | -0.10 | |||||
Company overview
Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19. Founded in 2019, Ocean Biomedical's operations are headquartered in Providence, Rhode Island.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ocean Biomedical, Inc. (OCEAW)
Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19. Founded in 2019, Ocean Biomedical's operations are headquartered in Providence, Rhode Island.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free